Androniki Bili

Rheumatology

3400 Civic Center Boulevard
South Pavilion, 1st Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study.

Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study.

Journal: Journal of the American Academy of Dermatology

Published: April 03, 2025

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.

Journal: Dermatology and therapy

Published: February 04, 2025

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

Journal: Vaccine

Published: April 05, 2022

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.

Journal: Human vaccines & immunotherapeutics

Published: March 15, 2022

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).

Journal: RMD open

Published: September 29, 2020

Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.

Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 28, 2019

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.

Journal: Journal of the American Heart Association

Published: January 06, 2016

Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients.

Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients.

Journal: Rheumatology international

Published: June 23, 2014

Low vitamin D level is not associated with increased incidence of rheumatoid arthritis.

Low vitamin D level is not associated with increased incidence of rheumatoid arthritis.

Journal: Rheumatology international

Published: January 05, 2014

Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease.

Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease.

Journal: ISRN rheumatology

Published: August 19, 2013

Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis.

Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis.

Journal: Arthritis care & research

Published: January 05, 2013

Tumor necrosis factor-α inhibitor use is not associated with lipid changes in rheumatoid arthritis.

Tumor necrosis factor-α inhibitor use is not associated with lipid changes in rheumatoid arthritis.

Journal: The Journal of rheumatology

Published: April 03, 2012

Showing 1-12 of 15

Last Updated: 09/26/2026